Business
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
SOUTH SAN FRANCISCO, Calif., February 04, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and pr
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/92f5321d4d7c71a67d527295925e3309"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GEDojsmz_s3CqUj6z3fSQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/92f5321d4d7c71a67d527295925e3309","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_GKHdqF3Z9.ipFRnq5Rhsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/92f5321d4d7c71a67d527295925e3309","width":1200,"height":325}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., February 04, 2026--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update.","length":542,"tagName":"p"},{"type":"text","content":"The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes before the call. The webcast will be archived on Vistagen’s website shortly after the call and will be available for at least 90 days.","length":385,"tagName":"p"},{"type":"text","content":"For participants interested in joining the call via dial-in, please follow the link below to pre-register. After registering, you will receive access to access details via email. https://register-conf.media-server.com/register/BI3bf0ee6127db48dcbce4d11a90b295b4","length":261,"tagName":"p"},{"type":"text","content":"About Vistagen","length":14,"tagName":"p"},{"type":"text","content":"Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neuroc...